Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Blueprint Medicines Corp (BPMC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/25/2023 8-K Other Events  Interactive Data
08/02/2023 8-K Quarterly results
06/30/2023 8-K Other Events  Interactive Data
05/25/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FIRST AMENDMENT TO FINANCING AGREEMENT"
05/04/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
02/27/2023 8-K Investor presentation
Docs: "INTRODUCTION CHIEF EXECUTIVE OFFICER BLUEPRINT MEDICINES KATE"
02/23/2023 8-K Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  ...
Docs: "Blueprint Medicines to Regain Global Rights to GAVRETO from Roche"
02/10/2023 8-K Quarterly results
01/09/2023 8-K Investor presentation
Docs: "KATE HAVILAND, PRESIDENT AND CEO J.P. MORGAN HEALTHCARE CONFERENCE"
01/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors"
12/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CONSULTING AGREEMENT",
"AMENDMENT AGREEMENT"
12/06/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF BLUEPRINT MEDICINES CORPORATION ARTICLE I Stockholders SECTION 1. Annual Meeting . The annual meeting of stockholders shall be held at the hour, date and place within or without the United States which is fixed by the Corporation’ s Board of Directors , which time, date and place may subsequently be changed at any time, before or after the notice for such meeting has been sent to the stockholders, by vote of the Board of Directors. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211 of the General Corporation Law of the State of Delaware . In the absence of any such designation or determination, ..."
11/01/2022 8-K Quarterly results
09/23/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement is dated as of September 23, 2022 , between Blueprint Medicines Corporation, a Delaware corporation , and Kathryn Haviland . Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement . WHEREAS, the Company and the Executive are parties to the Amended and Restated Employment Agreement dated as of January 4, 2022 and effective as of April 4, 2022 ; and WHEREAS, the Company and the Executive desire to amend the Employment Agreement as set forth below; NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby confirmed, the Company and the Executive agree that the Employment Agreem...",
"THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement is dated as of September 23, 2022 , between Blueprint Medicines Corporation, a Delaware corporation , and Michael Landsittel . Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement . WHEREAS, the Company and the Executive are parties to the Employment Agreement dated as of November 22, 2017, as amended by the First Amendment to Employment Agreement dated as of January 30, 2019, and as further amended by the Second Amendment to Employment Agreement dated as of December 22, 2021 ; and WHEREAS, the Company and the Executive desire to amend the Employment Agreement as set forth below; NOW, THEREFORE, for good and valuable consideration, the rec...",
"FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Amended and Restated Employment Agreement is dated as of September 23, 2022 , between Blueprint Medicines Corporation, a Delaware corporation , and Christina Rossi . Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement . WHEREAS, the Company and the Executive are parties to the Amended and Restated Employment Agreement dated January 4, 2022 and effective as of April 4, 2022 ; and WHEREAS, the Company and the Executive desire to amend the Employment Agreement as set forth below; NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby confirmed, the Company and the Executive agree that the Employment Agreement is ...",
"SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement is dated as of September 23, 2022 , between Blueprint Medicines Corporation, a Delaware corporation , and Fouad Namouni, M.D. . Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement . WHEREAS, the Company and the Executive are parties to the Employment Agreement effective as of September 1, 2020, as amended by the First Amendment to Employment Agreement dated as of December 22, 2021 ; and WHEREAS, the Company and the Executive desire to amend the Employment Agreement as set forth below; NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby confirmed, the Company and the Executive agree that the Employment Agr...",
"SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement is dated as of September 23, 2022 , between Blueprint Medicines Corporation, a Delaware corporation , and Tracey McCain . Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement . WHEREAS, the Company and the Executive are parties to the Employment Agreement dated as of September 6, 2016, as amended by the First Amendment to Employment Agreement dated as of December 22, 2021 ; and WHEREAS, the Company and the Executive desire to amend the Employment Agreement as set forth below; NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby confirmed, the Company and the Executive agree that the Employment Agreement is ...",
"SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT",
"SECOND AMENDMENT TO EMPLOYMENT AGREEMENT",
"SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement is dated as of September 23, 2022 , between Blueprint Medicines Corporation, a Delaware corporation , and Percy Carter Ph. D., MBA . Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement . WHEREAS, the Company and the Executive are parties to the Employment Agreement effective as of May 19, 2021, as amended by the First Amendment to Employment Agreement dated as of December 22, 2021 ; and WHEREAS, the Company and the Executive desire to amend the Employment Agreement as set forth below; NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby confirmed, the Company and the Executive agree that the Employment Agr...",
"THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement is dated as of September 23, 2022 , between Blueprint Medicines Corporation, a Delaware corporation , and Debra Durso-Bumpus . Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement . WHEREAS, the Company and the Executive are parties to the Employment Agreement dated as of November 22, 2017, as amended by the First Amendment to Employment Agreement dated as of February 10, 2020, and the Second Amendment to Employment Agreement dated as of December 22, 2021 ; and WHEREAS, the Company and the Executive desire to amend the Employment Agreement as set forth below; NOW, THEREFORE, for good and valuable consideration, the receipt of which is here...",
"SECOND AMENDMENT TO EMPLOYMENT AGREEMENT"
09/07/2022 8-K Investor presentation
Docs: "BLUEPRINT MEDICINES COMPANY OVERVIEW SEPTEMBER 2022"
08/17/2022 8-K Quarterly results
08/02/2022 8-K Quarterly results
Docs: "Blueprint Medicines Reports Second Quarter 2022 Results"
06/30/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
04/29/2022 8-K Quarterly results
04/08/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "31, 2021. 4 STRONG FINANCIAL POSITION WITH",
"Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer"
02/28/2022 8-K Quarterly results
02/16/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results"
01/20/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Blueprint Medicines Elevates Two Talented Leaders to its Executive Team",
"AMENDED & RESTATED"
01/10/2022 8-K Investor presentation
Docs: "OUR FIRST DECADE OF ACHIEVEMENT",
"Investor Contact"
01/05/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDED & RESTATED",
"AMENDED & RESTATED",
"AMENDED & RESTATED EMPLOYMENT AGREEMENT This Amended & Restated Employment Agreement is between Blueprint Medicines Corporation, a Delaware corporation , and Christina Rossi and is effective as of April 4, 2022 . WHEREAS, the Company and the Executive are parties to the Employment Agreement dated as of October 29, 2018, as amended by a first amendment thereto dated as of December 22, 2021 ; WHEREAS, the Company and the Executive desire to enter into this Agreement effective as of the Effective Date to replace the Original Employment Agreement, provided the Executive is employed by the Company on the Effective Date; and WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein. NOW, THEREFORE, in...",
"Blueprint Medicines Announces CEO and Leadership Transition Plan"
12/30/2021 8-K Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits &n...
Docs: "CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND",
"Blueprint Medicines Completes Acquisition of Lengo Therapeutics"
12/23/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "First Amendment to Employment Agreement, by and between the Registrant and Jeffrey W. Albers",
"Second Amendment to Employment Agreement, by and between the Registrant and Michael Landsittel",
"First Amendment to Employment Agreement, by and between the Registrant and Fouad Namouni",
"Second Amendment to Employment Agreement, by and between the Registrant and Kathryn Haviland",
"First Amendment to Employment Agreement, by and between the Registrant and Tracey L. McCain",
"First Amendment to Employment Agreement, by and between the Registrant and Christina Rossi",
"First Amendment to Amended and Restated Employment Agreement, by and between the Registrant and Becker Hewes",
"First Amendment to Employment Agreement, by and between the Registrant and Christopher Murray",
"First Amendment to Employment Agreement, by and between the Registrant and Percy H. Carter",
"Second Amendment to Employment Agreement, by and between the Registrant and Debra Durso-Bumpus"
12/09/2021 8-K Quarterly results
11/29/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics",
"3 LEADER IN PRECISION THERAPY LNG"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy